IL128956A0 - Olanzapine dihydrate D - Google Patents

Olanzapine dihydrate D

Info

Publication number
IL128956A0
IL128956A0 IL12895697A IL12895697A IL128956A0 IL 128956 A0 IL128956 A0 IL 128956A0 IL 12895697 A IL12895697 A IL 12895697A IL 12895697 A IL12895697 A IL 12895697A IL 128956 A0 IL128956 A0 IL 128956A0
Authority
IL
Israel
Prior art keywords
olanzapine dihydrate
olanzapine
dihydrate
Prior art date
Application number
IL12895697A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21832112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL128956(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL128956A0 publication Critical patent/IL128956A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL12895697A 1996-09-23 1997-09-18 Olanzapine dihydrate D IL128956A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2648696P 1996-09-23 1996-09-23
PCT/US1997/016586 WO1998011893A1 (en) 1996-09-23 1997-09-18 Olanzapine dihydrate d

Publications (1)

Publication Number Publication Date
IL128956A0 true IL128956A0 (en) 2000-02-17

Family

ID=21832112

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12895697A IL128956A0 (en) 1996-09-23 1997-09-18 Olanzapine dihydrate D

Country Status (34)

Country Link
US (1) US6251895B1 (cs)
EP (1) EP0831097B1 (cs)
JP (1) JP2001500878A (cs)
KR (1) KR100516088B1 (cs)
CN (1) CN1146567C (cs)
AR (1) AR009801A1 (cs)
AT (1) ATE221074T1 (cs)
AU (1) AU720366B2 (cs)
BR (1) BR9711541A (cs)
CA (1) CA2266444C (cs)
CO (1) CO4900057A1 (cs)
CZ (1) CZ299247B6 (cs)
DE (1) DE69714165T2 (cs)
DK (1) DK0831097T3 (cs)
EA (1) EA001881B1 (cs)
EG (1) EG23815A (cs)
ES (1) ES2180899T3 (cs)
HU (1) HU226167B1 (cs)
ID (1) ID21924A (cs)
IL (1) IL128956A0 (cs)
MY (1) MY125467A (cs)
NO (1) NO323979B1 (cs)
NZ (1) NZ334346A (cs)
PE (1) PE110298A1 (cs)
PL (1) PL194074B1 (cs)
PT (1) PT831097E (cs)
RS (1) RS49597B (cs)
SI (1) SI0831097T1 (cs)
SV (1) SV1997000079A (cs)
TR (1) TR199900639T2 (cs)
TW (1) TW518335B (cs)
UA (1) UA56184C2 (cs)
WO (1) WO1998011893A1 (cs)
ZA (1) ZA978512B (cs)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
ATE359793T1 (de) * 1998-09-30 2007-05-15 Lilly Co Eli 2-methyl-thieno-benzodiazepin formulierung
ES2240215T3 (es) * 1999-12-28 2005-10-16 Cipla Limited Nuevas formas polimorfas de olanzapina.
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
EP1313742A1 (en) * 2000-08-31 2003-05-28 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
WO2003037903A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
AU2003237305A1 (en) * 2002-05-31 2003-12-19 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
ES2289974T1 (es) * 2004-07-14 2008-02-16 Shasun Chemicals And Drugs Limited Metodo mejorado para producir la forma i de la olanzapina.
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
ES2303462B1 (es) 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
KR20070058537A (ko) 2004-09-29 2007-06-08 바이엘 헬스케어 아게 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US7834176B2 (en) * 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA015687B1 (ru) 2006-05-04 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Полиморфы
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
CN102036654B (zh) * 2008-07-24 2014-05-14 湖南洞庭药业股份有限公司 稳定的非典型抗精神病制剂
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP2016027003A (ja) * 2012-11-20 2016-02-18 大蔵製薬株式会社 長期間安定なオランザピンの水性医薬製剤
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302716A (en) * 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
AU668159B2 (en) * 1992-05-29 1996-04-26 Lilly Industries Limited Pharmaceutical compounds
EP0766635A1 (en) 1994-06-28 1997-04-09 W.R. Grace & Co.-Conn. Bag having protective patches
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
CN1234738A (zh) 1999-11-10
HUP0000065A2 (hu) 2000-06-28
EA199900325A1 (ru) 1999-08-26
SV1997000079A (es) 1999-01-13
PT831097E (pt) 2002-10-31
UA56184C2 (uk) 2003-05-15
US6251895B1 (en) 2001-06-26
RS49597B (sr) 2007-06-04
DE69714165T2 (de) 2003-01-23
HK1009809A1 (en) 1999-06-11
ID21924A (id) 1999-08-12
TR199900639T2 (xx) 1999-06-21
ZA978512B (en) 1999-03-23
NO323979B1 (no) 2007-07-30
DK0831097T3 (da) 2002-09-02
PL332541A1 (en) 1999-09-13
EG23815A (en) 2007-08-19
ATE221074T1 (de) 2002-08-15
DE69714165D1 (de) 2002-08-29
TW518335B (en) 2003-01-21
HUP0000065A3 (en) 2000-11-28
CO4900057A1 (es) 2000-03-27
KR100516088B1 (ko) 2005-09-22
EP0831097B1 (en) 2002-07-24
ES2180899T3 (es) 2003-02-16
AU720366B2 (en) 2000-06-01
CA2266444C (en) 2007-01-09
CA2266444A1 (en) 1998-03-26
KR20000048519A (ko) 2000-07-25
NZ334346A (en) 2000-05-26
CZ299247B6 (cs) 2008-05-28
CN1146567C (zh) 2004-04-21
MY125467A (en) 2006-08-30
PL194074B1 (pl) 2007-04-30
YU15499A (sh) 2000-03-21
WO1998011893A1 (en) 1998-03-26
EA001881B1 (ru) 2001-10-22
BR9711541A (pt) 1999-08-24
CZ98999A3 (cs) 1999-08-11
HU226167B1 (hu) 2008-05-28
EP0831097A2 (en) 1998-03-25
SI0831097T1 (en) 2003-02-28
NO991339D0 (no) 1999-03-19
PE110298A1 (es) 1999-01-18
EP0831097A3 (en) 1998-04-29
AR009801A1 (es) 2000-05-03
NO991339L (no) 1999-03-19
JP2001500878A (ja) 2001-01-23
AU4424197A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
IL128956A0 (en) Olanzapine dihydrate D
DE59709404D1 (en) Thienopyrimidine
ZA979516B (en) Thienopyrimidines.
PL331557A1 (en) Arylakanoyl pyridiazines
PL341156A1 (en) Thienopyrimidines
DE59704086D1 (en) Twin-dualmode-filter
IL130046A0 (en) Improved object manufacture
DE69724744D1 (en) Reversibles optisches informationsmedium
AU131132S (en) Handleset
DE59702027D1 (en) Bragg-modulator
AU131198S (en) Handleset
AU131199S (en) Handleset
GB9625186D0 (en) Manufacture
DE59610178D1 (en) Rotationspumpe
GB9723445D0 (en) Manufacture
CA79582S (en) Jerkin
AU1593P (en) Songlines Telopea speciosissima
ZA9710454B (en) Improved object manufacture
GB9602765D0 (en) Publicans pipecleaning aid
GB9610660D0 (en) Safetyt aid
GB9618273D0 (en) Diaper
GB9626008D0 (en) Diaper
GB9613195D0 (en) Diaper
GB9620997D0 (en) Void former
GB9625866D0 (en) Cistern

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees